Cost-effectiveness of trastuzumab in metastatic breast cancer: Mainly a matter of price in the EU?
Year of publication: |
2015
|
---|---|
Authors: | Garattini, Livio ; van de Vooren, Katelijne ; Curto, Alessandro |
Published in: |
Health Policy. - Elsevier, ISSN 0168-8510. - Vol. 119.2015, 2, p. 212-216
|
Publisher: |
Elsevier |
Subject: | Economic evaluation | Health technology assessment | Trastuzumab | Metastatic breast cancer | Biosimilars |
-
Essential notion of the health economic evaluation: Definition
Botchkarev, Alexei, (2016)
-
Halton, Kate Amanda, (2009)
-
Taxonomy for methods of resource use measurement
Ridyard, Colin H., (2015)
- More ...
-
Pricing of forthcoming therapies for hepatitis C in Europe : beyond cost-effectiveness?
Van de Vooren, Katelijne, (2015)
-
Italian risk-sharing agreements on drugs : are they worthwhile?
Garattini, Livio, (2015)
-
Western European Markets for biosimilar and generic drugs : worth differentiating : Editorial
Garattini, Livio, (2015)
- More ...